(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual revenue growth rate of 46.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Day One Biopharmaceuticals's revenue in 2025 is $131,161,000.On average, 4 Wall Street analysts forecast DAWN's revenue for 2025 to be $16,213,884,634, with the lowest DAWN revenue forecast at $13,733,536,918, and the highest DAWN revenue forecast at $18,970,524,760. On average, 4 Wall Street analysts forecast DAWN's revenue for 2026 to be $26,757,085,451, with the lowest DAWN revenue forecast at $20,605,373,103, and the highest DAWN revenue forecast at $31,613,487,086.
In 2027, DAWN is forecast to generate $43,134,049,501 in revenue, with the lowest revenue forecast at $36,390,325,425 and the highest revenue forecast at $50,097,510,168.